A cannabinoid 2 receptor agonist attenuates bone cancer-induced pain and bone loss

AN Lozano-Ondoua, C Wright, A Vardanyan, T King… - Life sciences, 2010 - Elsevier
AN Lozano-Ondoua, C Wright, A Vardanyan, T King, TM Largent-Milnes, M Nelson…
Life sciences, 2010Elsevier
AIMS: Cannabinoid CB2 agonists have been shown to alleviate behavioral signs of
inflammatory and neuropathic pain in animal models. AM1241, a CB2 agonist, does not
demonstrate central nervous system side effects seen with CB1 agonists such as
hypothermia and catalepsy. Metastatic bone cancer causes severe pain in patients and is
treated with analgesics such as opiates. Recent reports suggest that sustained opiates can
produce paradoxical hyperalgesic actions and enhance bone destruction in a murine model …
AIMS
Cannabinoid CB2 agonists have been shown to alleviate behavioral signs of inflammatory and neuropathic pain in animal models. AM1241, a CB2 agonist, does not demonstrate central nervous system side effects seen with CB1 agonists such as hypothermia and catalepsy. Metastatic bone cancer causes severe pain in patients and is treated with analgesics such as opiates. Recent reports suggest that sustained opiates can produce paradoxical hyperalgesic actions and enhance bone destruction in a murine model of bone cancer. In contrast, CB2 selective agonists have been shown to reduce bone loss associated with a model of osteoporosis. Here we tested whether a CB2 agonist administered over a 7day period inhibits bone cancer-induced pain as well as attenuates cancer-induced bone degradation.
MAIN METHODS
A murine bone cancer model was used in which osteolytic sarcoma cells were injected into the intramedullary space of the distal end of the femur. Behavioral and radiographic image analysis was performed at days 7, 10 and 14 after injection of tumor cells into the femur.
KEY FINDINGS
Osteolytic sarcoma within the femur produced spontaneous and touch evoked behavioral signs of pain within the tumor-bearing limb. The systemic administration of AM1241 acutely or for 7days significantly attenuated spontaneous and evoked pain in the inoculated limb. Sustained AM1241 significantly reduced bone loss and decreased the incidence of cancer-induced bone fractures.
SIGNIFICANCE
These findings suggest a novel therapy for cancer-induced bone pain, bone loss and bone fracture while lacking many unwanted side effects seen with current treatments for bone cancer pain.
Elsevier
以上显示的是最相近的搜索结果。 查看全部搜索结果